Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis

Abstract

BackgroundThere are few published estimates of the cost of pediatric antiretroviral therapy (ART) in Africa. Our objective was to estimate the outpatient cost of providing ART to children remaining in care at six public sector clinics in Zambia during the first three years after ART initiation, stratified by service delivery site and time on treatment.MethodsData on resource utilization (drugs, diagnostics, outpatient visits, fixed costs) and treatment outcomes (in care, died, lost to follow up) were extracted from medical records for 1,334 children at six sites who initiated ART at <15 years of age between 2006 and 2011. Fixed and variable unit costs (reported in 2011 USD) were estimated from the provider’s perspective using site level data.ResultsMedian age at ART initiation was 4.0 years; median CD4 percentage was 14%. One year after ART initiation, 73% of patients remained in care, ranging from 60% to 91% depending on site. The average annual outpatient cost per patient remaining in care was $209 (95% CI, $199–$219), ranging from $116 (95% CI, $107–$126) to $516 (95% CI, $499–$533) depending on site. Average annual costs decreased as time on treatment increased. Antiretroviral drugs were the largest component of all outpatient costs (>50%) at four sites. At the two remaining sites, outpatient visits and fixed costs together accounted for >50% of outpatient costs. The distribution of costs is slightly skewed, with median costs 3% to 13% lower than average costs during the first year after ART initiation depending on site.ConclusionsOutpatient costs for children initiating ART in Zambia are low and comparable to reported outpatient costs for adults. Outpatient costs and retention in care vary widely by site, suggesting opportunities for efficiency gains. Taking advantage of such opportunities will help ensure that targets for pediatric treatment coverage can be met.

Retention of HIV-Infected Children in the First 12 Months of Anti-Retroviral Therapy and Predictors of Attrition in Resource Limited Settings: A Systematic Review

“…Only one study from Zambia purposively selected 6 sites to represent different health facility levels. [ 20 ] Most sites from the included articles were public (government) facilities in urban areas. Detailed site information is available in Table 2 .…”

The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020

“…Facility-based studies that estimated unit costs for pediatric HIV treatment found that they are often comparable to adult HIV treatment costs [ 73 ]. The average annual cost of providing ART to a child in Zambia was US$209 in 2011, ranging from US$116 to US$516 depending on site [ 59 ]. The cost is higher in South Africa: the first-year average cost per child in care and responding to treatment was US$830 at one site and US$678 at another [ 41 ].…”

Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age

“…Finally, we did not have detailed data for children in Côte d’Ivoire; we used clinical data from East and Southern Africa and varied only costs. Although our approach to deriving healthcare costs matched published economic data from South Africa and Zambia (a low-income country with GDP similar to Côte d’Ivoire), such an approach excluded country-specific factors, such as reduced malaria risk with protease inhibitors, which might change the clinical and cost-effectiveness of first-line lopinavir/ritonavir [ 36 , 51 , 52 ].…”